Daily Newsletter

31 July 2023

Daily Newsletter

31 July 2023

Lupin recalls pregnancy prevention drug Tydemy

The tablets were recalled because of out-of-specification test results at the 12-month stability time point.

RanjithKumar Dharma July 31 2023

Lupin Pharmaceuticals has announced the voluntary recall of two lots of the pregnancy prevention drug Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium tablets 3mg/0.03mg/0.451mg and levomefolate calcium tablets 0.451mg) in the US.

Tydemy is an estrogen/progestin oral contraceptive (COC) intended for women who wish to prevent pregnancy and for increasing folate levels in those who choose an oral contraceptive.

The tablets have been recalled because of out-of-specification (OOS) test results at the 12-month stability time point. 

One lot in particular, L200183, tested low for ascorbic acid (an inactive ingredient), and also high for a known impurity.

Lupin is recalling the two lots due to a significant reduction in their inactive content (ascorbic acid), which may potentially impact the product's effectiveness and result in unexpected pregnancies.

Tydemy is delivered in blister packs containing 28 tablets each. A single blister was packed into a pouch, along with a printed sleeve, a pack insert labelled with the day and an oxygen absorber sachet (Stabilox).

The three pouches were packed in a single carton. The lots were then supplied across the US to wholesalers, mail-order pharmacies, drug chains and supermarkets.

Adverse reactions or quality problems with this product can be reported to the US Food and Drug Administration (FDA) MedWatch Adverse Event Reporting Programme online by regular mail or by fax.

So far, Lupin has not received any reports of adverse events associated with the recalled lots.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close